Daniela Rogoff, MD, Phd

  • Vice President, Clinical Development
  • QED Therapeutics

A subsidiary of BridgeBio, QED focuses on precision medicine for FGFR-driven cancers and conditions. We live by our name: QED, derived from the Latin “Quod Erat Demonstrandum” —Thus, It Has Been Proven.

Our business is inspired by our values –

PUT PATIENTS FIRST
THINK INDEPENDENTLY
BE RADICALLY TRANSPARENT
EVERY MINUTE COUNTS
LET SCIENCE SPEAK

What we do
With singular focus, QED is devoted to the development of our investigational candidate, infigratinib. A first-in-class, selective, tyrosine kinase inhibitor, infigratinib has promising early clinical data in patients with previously treated, FGFR-driven cholangiocarcinoma and metastatic urothelial carcinoma, as well as preclinical studies in achondroplasia. Future studies will investigate infigratinib for additional FGFR-driven tumor types and rare disorders.


Achondroplasia affects approximately 1 out every 20,000 newborns, and treatment advances for children with this bone growth disorder have been limited. Children with achondroplasia reach an adult height of 4 feet 10 inches or shorter and may also experience serious, often debilitating health complications. FGFR genetic alterations can cause more than 99% of achondroplasia cases.

Session

  • Infigratinib for Achondroplasia

    The latest information on the development of Infigratinib for patients with achondroplasia. Infigratinib is an orally bioavailable and selective FGFR1/2/3 selective tyrosine kinase inhibitor in development for FGFR-related conditions. Infigratinib in children with achondroplasia (ACH): design of PROPEL2 – a phase 2, open-label, dose-escalation and dose-expansion study